CN114555083A - 食欲素2受体激动剂用于治疗过度嗜睡的用途 - Google Patents

食欲素2受体激动剂用于治疗过度嗜睡的用途 Download PDF

Info

Publication number
CN114555083A
CN114555083A CN202080072019.0A CN202080072019A CN114555083A CN 114555083 A CN114555083 A CN 114555083A CN 202080072019 A CN202080072019 A CN 202080072019A CN 114555083 A CN114555083 A CN 114555083A
Authority
CN
China
Prior art keywords
compound
subject
effective amount
plasma concentration
sleepiness
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080072019.0A
Other languages
English (en)
Chinese (zh)
Inventor
D·哈特曼
R·伊文思
H·费塞尔
R·鲁本斯
S·田中
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of CN114555083A publication Critical patent/CN114555083A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202080072019.0A 2019-09-13 2020-09-12 食欲素2受体激动剂用于治疗过度嗜睡的用途 Pending CN114555083A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962900310P 2019-09-13 2019-09-13
US62/900,310 2019-09-13
US202063031687P 2020-05-29 2020-05-29
US63/031,687 2020-05-29
PCT/IB2020/058482 WO2021048821A1 (en) 2019-09-13 2020-09-12 Use of an orexin 2 receptor agonist for the treatment of excessive sleepiness

Publications (1)

Publication Number Publication Date
CN114555083A true CN114555083A (zh) 2022-05-27

Family

ID=72521681

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080072019.0A Pending CN114555083A (zh) 2019-09-13 2020-09-12 食欲素2受体激动剂用于治疗过度嗜睡的用途

Country Status (11)

Country Link
US (1) US20220331303A1 (https=)
EP (1) EP4028003A1 (https=)
JP (1) JP2022547604A (https=)
KR (1) KR20220062361A (https=)
CN (1) CN114555083A (https=)
AU (1) AU2020347578A1 (https=)
BR (1) BR112022004576A2 (https=)
CA (1) CA3154320A1 (https=)
CO (1) CO2022004589A2 (https=)
MX (1) MX2022003017A (https=)
WO (1) WO2021048821A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4065585B1 (en) 2019-11-25 2025-08-20 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
AU2021205892B2 (en) 2020-01-10 2026-04-23 Takeda Pharmaceutical Company Limited A method for enhancing the pharmacokinetics or increasing the plasma concentration of methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate or a salt thereof with an inhibitor of cytochrome P450
CN116583502A (zh) 2020-09-03 2023-08-11 欧瑞夏治疗有限公司 二环-杂环衍生物及其作为食欲素-2受体激动剂的用途
US12006330B2 (en) 2020-12-21 2024-06-11 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
WO2024075825A1 (ja) 2022-10-07 2024-04-11 キッセイ薬品工業株式会社 シクロペンタン化合物
EP4719397A1 (en) * 2023-06-02 2026-04-08 Takeda Pharmaceutical Company Limited Use of an orexin 2 receptor agonist for improving respiratory function during sleep
WO2025124698A1 (en) 2023-12-12 2025-06-19 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators
TW202542165A (zh) 2023-12-19 2025-11-01 瑞士商愛杜西亞製藥有限公司 大環食慾素激動劑

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108884043A (zh) * 2016-02-04 2018-11-23 武田药品工业株式会社 取代的哌啶化合物及其用途
CN109689058A (zh) * 2016-07-26 2019-04-26 普渡制药公司 治疗和预防睡眠障碍

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0815134B1 (en) 1995-03-14 2002-06-05 Praecis Pharmaceuticals Incorporated Modulators of amyloid aggregation
PT929574E (pt) 1996-08-27 2005-11-30 Praecis Pharm Inc Moduladores da agregacao de peptidos beta-amiloides compreendendo d-aminoacidos
EP1196609A2 (en) 1999-06-28 2002-04-17 Oklahoma Medical Research Foundation Catalytically active recombinant memapsin and methods of use thereof
AU2020346456A1 (en) * 2019-09-13 2022-04-14 Takeda Pharmaceutical Company Limited TAK-925 for use in treating narcolepsy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108884043A (zh) * 2016-02-04 2018-11-23 武田药品工业株式会社 取代的哌啶化合物及其用途
CN109689058A (zh) * 2016-07-26 2019-04-26 普渡制药公司 治疗和预防睡眠障碍

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SUZUKI M ET AL.: ""AN OREXIN 2 RECEPTOR-SELECTIVE AGONIST TAK-925 AMELIORATES NARCOLEPSY-LIKE SYMPTOMS IN OREXIN/ATAXIN-3 MICE"", 《SLEEP》, vol. 41, pages 1 *

Also Published As

Publication number Publication date
US20220331303A1 (en) 2022-10-20
KR20220062361A (ko) 2022-05-16
MX2022003017A (es) 2022-06-14
CA3154320A1 (en) 2021-03-18
JP2022547604A (ja) 2022-11-14
EP4028003A1 (en) 2022-07-20
CO2022004589A2 (es) 2022-04-29
WO2021048821A1 (en) 2021-03-18
WO2021048821A8 (en) 2021-11-04
AU2020347578A1 (en) 2022-04-14
BR112022004576A2 (pt) 2022-06-14

Similar Documents

Publication Publication Date Title
CN114555083A (zh) 食欲素2受体激动剂用于治疗过度嗜睡的用途
CN114980892A (zh) 用于治疗发作性睡病的tak-925
TWI298254B (en) Use of optically pure (s,s) -reboxetine in the manufacture of a medicament for the treatment or prevention of chronic fatigue syndrome
US9700548B2 (en) Antihistamines combined with dietary supplements for improved health
JP2008519847A (ja) 運動障害の治療方法
WO2023186829A1 (en) 5-methoxy-n,n-dimethyltryptamine for the treatment of social/emotional withdrawal or detachment
JP2025510294A (ja) 精神運動遅滞の治療のための５－メトキシ－ｎ，ｎ－ジメチルトリプタミン
CN114786660A (zh) 使用mtorc1调节剂的治疗方法
Thase et al. Clinical relevance of disturbances of sleep and vigilance in major depressive disorder: a review
US20040167164A1 (en) Compositions and methods for treating particular chemical addictions and mental illnesses
US20010047010A1 (en) Compositions and methods for treating particular chemical addictions and mental illnesses
TW202302100A (zh) 食慾激素２受體促效劑於治療食慾激素介導之疾病或病症之用途
US20240284941A1 (en) Antihistamines combined with dietary supplements for improved health
CN118973569A (zh) 用于治疗双相情感障碍的5-甲氧基-n,n-二甲基色胺
KR20250134717A (ko) 산후 우울증의 치료에 사용하기 위한 5-meo-dmt
KR20240167885A (ko) 산후 우울증 치료에 사용하기 위한 5-meo-dmt
JPH03246225A (ja) メランコリーうつ病の治療法
WO2010136964A1 (en) Method of treating sleep disorders using the combination of eplivanserin and zolpidem

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220527

WD01 Invention patent application deemed withdrawn after publication